Personalis won CE-IVD marking for its EDTA and cfDNA blood collection kits in the EU, clearing the way to market the specimen products that support its ultrasensitive NeXT Personal assay. The kits are intended to help preserve sample integrity for genomic analysis and MRD testing. The update matters commercially because standardized specimen collection can reduce variability across multicenter trials and improve the reliability of downstream MRD readouts. Personalis said the CE-IVD milestone positions the company to support larger global clinical studies. Personalis also pointed to recent Medicare coverage for NeXT Personal in late-stage triple-negative or HER2-positive breast cancer and for immunotherapy monitoring across multiple late-stage solid tumors, reinforcing momentum for scale deployment.